Sigyn Therapeutics (SIGY) Debt Ratio (2017 - 2025)
Sigyn Therapeutics (SIGY) posted Debt Ratio of 17.47 for Q3 2025, up 244.97% sequentially from 5.06 in Q2 2025.
Sigyn Therapeutics (SIGY) Debt Ratio (2017 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Debt Ratio for 4 years, with the latest figure at 17.47 in Q3 2025.
- Quarterly Debt Ratio changed N/A year-over-year to 17.47 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 17.47 (changed N/A YoY) and the FY2024 annual result came in at 9.67, changed N/A from the prior year.
- Debt Ratio grew to 17.47 in Q3 2025 per SIGY's latest filing, from 5.06 in the prior quarter.
- Over five years, Debt Ratio peaked at 17.47 in Q3 2025 and troughed at 0.87 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | 0.05 |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 0.12 |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.03 |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | 0.26 |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 0.47 |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | 20.76 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 17.47 |
| Jun 30, 2025 | 5.06 |
| Mar 31, 2025 | 0.87 |
| Dec 31, 2024 | 9.67 |
| Sep 30, 2019 | 0.05 |
| Dec 31, 2017 | 0.01 |
| Jun 30, 2017 | 0.01 |